Evidence map›Paper›PMID 25886677›Full record

SynthesisCanadian journal of psychiatry. Revue canadienne de psychiatrie2015

Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.

Stéphane Potvin, Simon Zhornitsky, Emmanuel Stip

Abstract readMeta-Analysis
PubMed Full text at PMC
In one paragraph

Synthesis in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Stéphane PotvinResearcher, Centre de recherche de l'Institut Universitaire en Santé Mentale de Montréal, Montreal, Quebec; Associate Research Professor, Department of Psychiatry, University of Montreal, Montreal, Quebec.
Simon ZhornitskyPostdoctoral Fellow, Multiple Sclerosis Research Program, Foothills Medical Centre, Calgary, Alberta; Postdoctoral Fellow, Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Calgary, Alberta.
Emmanuel StipPsychiatrist and Professor, Department of Psychiatry, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec; Chair, Department of Psychiatry, Faculty of Medicine, University of Montreal, Montreal, Quebec; Eli Lilly Chair of Schizophrenia, University of Montreal, Montreal, Quebec.
Centre Hospitalier de l’Université de Montréal · CAFoothills Medical Centre · CAInstitut Universitaire en Santé Mentale de Québec · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWeight gain is a major side effect of antipsychotics (APs), which contributes to poor treatment adherence and significant morbidity. The mechanisms involved in AP-induced weight gain are incompletely understood. Recently, it has been proposed that changes in leptin, an cadipocyte-derived hormone exerting anorexigenic effects, may be involved in AP-induced weight gain. Thus far, studies on leptin changes during AP treatment have produced inconsistent results, prompting our group to perform a meta-analysis.

methodA search of the literature was performed using PubMed and Embase. Studies were included only if reporting peripheral levels of leptin before and after AP treatment in schizophrenia. Effect size estimates were calculated with Hedges g and were aggregated using a random effects model as results were heterogeneous (P<0.10). Meta-regression analyses were performed using study length and changes in body mass index (BMI) as moderator variables.

resultsTwenty-eight studies were retrieved, including 39 comparisons. A moderate and positive effect size was observed across studies. Olanzapine, clozapine, and quetiapine produced moderate leptin elevations, whereas haloperidol and risperidone were associated with small (nonsignificant) leptin changes. Across studies, BMI changes were significantly associated with increases in leptin levels. There was no effect of sex on AP-induced changes in leptin.

conclusionsA physiological role of leptin in AP-induced weight gain is supported because the most significant leptin increases were observed with APs inducing the most weight gain and because of the observed association between leptin increases and BMI changes. The overall increase in leptin levels suggests that leptin acts as a negative feedback signal in the event of fat increase.

Indexed as

Antipsychotic AgentsHumansLeptinSchizophreniaWeight GainAntipsychotic AgentsLeptin

Identifiers

PMID25886677
PMCPMC4418620
OpenAlexW1530804589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.